Acquisition of Patents and Intangibles (Tables)

12 Months Ended

May 31, 2019

Summary of the Net Purchase Price and Allocation to the Acquired Assets

A summary of the net purchase price and allocation to the acquired assets is as follows:

	Prostagene LLC
CytoDyn Inc. Equity	$	11,558,000
Acquisition Expenses		741,297
Release of Deferred Tax Asset		2,826,919
Total Cost of Acquisition	$	15,126,216
Intangible Assets	$	15,126,216
Other		—
Allocation of Acquisition Costs	$	15,126,216

Intangible Assets Activity

The following presents intangible assets activity, inclusive of patents:

	May 31, 2019			May 31, 2018
Gross carrying amounts	$	3,500,000		$	3,500,000
Intangible asset acquisition:
Prostagene, LLC		15,126,216			—
Website development costs		19,553
Accumulated amortization		(3,170,315	)		(1,968,846	)
Total amortizable intangible assets, net		15,475,454			1,531,154
Patents currently not amortized		—			35,989
Carrying value of intangibles, net	$	15,475,454		$	1,567,143